Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in hematocrit after coronary stent placement and dextran therapy

W H Haught1, M Sokol, R A Kerensky

  • 1Department of Medicine, College of Medicine, University of Florida, Gainesville 32610-0277, USA.

The American Journal of Cardiology
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simple model to incorporate statistical noise based on a modified hodgkin-huxley approach for external electrical field driven neural responses.

Biomedical physics & engineering express·2024
Same author

Magnetic properties of (Fe<sub>1-<i>x</i></sub>Mn<sub><i>x</i></sub>)<sub>2</sub>AlB<sub>2</sub> and the impact of substitution on the magnetocaloric effect.

Physical review materials·2024
Same author

Full aperture backscatter diagnostics for characterization of laser plasma instabilities at the extreme light infrastructure (ELI) beamlines.

The Review of scientific instruments·2023
Same author

Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.

Vascular pharmacology·2023
Same author

Does aspirin save lives in patients with COVID-19?

Heart (British Cardiac Society)·2021
Same author

Validated HPLC method for paclitaxel determination in PLGA submicron particles conjugated with α-fetoprotein third domain: Sample preparation case study.

Annales pharmaceutiques francaises·2021
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Dextran 40 administration post-coronary stent placement causes a significant, temporary drop in hematocrit due to hemodilution. This effect is often mistaken for blood loss, potentially leading to unnecessary transfusions.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Coronary stent placement is a common cardiovascular procedure.
  • Dextran 40 is sometimes used post-stenting, but its effects on hematocrit are not fully understood.
  • Accurate assessment of blood loss is critical in post-procedural patient management.

Purpose of the Study:

  • To investigate the impact of dextran 40 on hematocrit levels following coronary stent placement.
  • To differentiate dextran-induced hemodilution from actual blood loss.
  • To inform clinical practice regarding the interpretation of hematocrit changes in patients receiving dextran 40.

Main Methods:

  • Administration of dextran 40 to patients undergoing coronary stent placement.
  • Serial monitoring of hematocrit levels within 24 and 48 hours post-administration.

Related Experiment Videos

  • Analysis of hematocrit trends in relation to dextran 40 cessation.

    • Main Results:

    • A marked decrease in hematocrit was observed within 24 hours of dextran 40 administration.
    • Hematocrit levels typically returned to near baseline within 48 hours after discontinuing dextran 40.
    • The observed hematocrit decrease was attributed to dextran-related hemodilution.

    Conclusions:

    • Dextran 40 causes a transient hemodilutional decrease in hematocrit after coronary stenting.
    • This phenomenon can be misidentified as acute blood loss, potentially leading to unwarranted blood transfusions.
    • Alternative anticoagulation strategies not involving dextran are being explored for patients undergoing coronary stenting.